Moderna, ConocoPhillips, Vertex Pharmaceuticals And This ETF: CNBC's 'Final Trades'

On CNBC’s "Halftime Report Final Trades," Anastasia Amoroso of JP Morgan Private Bank named iShares Preferred and Income Securities ETF (NYSE: PFF) as her final trade.

Jim Lebenthal of Cerity Partners said Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a "new position" for him.

Vertex announced Health Canada market authorization for ORKAMBI in children with cystic fibrosis aged 1 to less than 2 years.

Don’t forget to check out our premarket coverage here.

Stephen Weiss of Short Hills Capital Partners named Moderna, Inc. (NASDAQ: MRNA) as his final trade.

Moderna said its first influenza candidate, mRNA-1010, did not accrue sufficient cases at the interim efficacy analysis to declare early success in the Phase 3 Northern Hemisphere efficacy trial and the independent DSMB recommended continuation of efficacy follow-up.

Joseph Terranova of Virtus Investment Partners picked ConocoPhillips (NYSE: COP).

ConocoPhillips disclosed a detailed 10-year operating and financial plan at an analyst & investor meeting. The company projects strong cash flow, with compounded annual growth rate (CAGR) in cash from operations and FCF of around 6% and 11%.

Price Action: ConocoPhillips shares rose 0.7% to close at $107.53, while Moderna rose 0.2% to settle at $155.56 on Wednesday. Vertex Pharmaceuticals shares added 0.5% to settle at $326.37 during the session.
Check This Out: Top 5 Financial Stocks That Are Set To Fly In April

Photo via Pixabay.